You are here
Development of Microalgal-Based Vaccines for Fish
Award Information
Agency: Department of Commerce
Branch: N/A
Contract: DG1330-02-CN-0063
Agency Tracking Number: 2001-220
Amount:
$199,650.00
Phase:
Phase II
Program:
SBIR
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Timeline
Solicitation Year:
N/A
Award Year:
2002
Award Start Date (Proposal Award Date):
N/A
Award End Date (Contract End Date):
N/A
Small Business Information
3416 Ashwood Drive, Bloomington, IN, 47401
DUNS:
N/A
HUBZone Owned:
N
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Principal Investigator
Name: Richard Wagner
Title: Chief Executive Officer
Phone: (812) 339-3057
Email: wagner@phycotransgenics.com
Title: Chief Executive Officer
Phone: (812) 339-3057
Email: wagner@phycotransgenics.com
Business Contact
Name: Richard Wagner
Title: Chief Executive Officer
Phone: (812) 339-3057
Email: wagner@phycotransgenics.com
Title: Chief Executive Officer
Phone: (812) 339-3057
Email: wagner@phycotransgenics.com
Research Institution
N/A
Abstract
Phycotransgenics goal is to develop a vaccine delivery system using microalgae to reduce diseaseassociated costs for aquaculture. To accomplish this, we transformed Chlamydomonas, a single-cell algal species, with an antigen gene. Through our Phase 1 Program, we demonstrated that: 1) an antigen expressed in our algae can elicit an immune response in fish, and; 2) using our microalgal delivery system, vaccines can be delivered to fish in several forms, as a feed, beverage, or immersion product. In Phase 2 we will develop a commercial prototype of our microalgal-based antigen delivery system. We will express an antigen of the IHN virus in our algae and conduct vaccine efficacy studies on fish challenged by IHNV. Fish will be vaccinated in an immersion bath or by medicated feed orally). The final objective of our research is to produce a mediated feed for oral vaccination that meets industry standards. * Information listed above is at the time of submission. *